The research – which looked at acceptability of potential future HIV vaccinations among high-risk adults in Los Angeles – shows many factors come into play when a person is deciding whether or not be vaccinated.
"As we can see in the current climate of confusion around H1N1 flu shots, the availability of a vaccination alone is not enough to encourage people to be inoculated," says lead author Peter A. Newman, associate professor at UofT's Factor-Inwentash Faculty of Social Work and Canada Research Chair in Health and Social Justice. "Our study shows the same holds true when it comes to potential HIV vaccines down the road. Even in the case of a safe and highly effective vaccine, there are a plethora of factors that impact peoples' decisions."
To determine what factors would make a vaccine "acceptable" to individuals at-risk of contracting HIV, Newman and his team gave each of 1,100 participants a set of nine cards outlining theoretical HIV vaccines. Each card described a theoretical HIV vaccine with a different combination of characteristics, including vaccine effectiveness, cost and side effects. Participants were then asked to rate the "acceptability" of each vaccine according to what vaccine characteristics were most and least important to them.
The team found a moderate level of acceptability for a future HIV vaccine – 55 on a 100-point scale. But while the moderate level of acceptability is positive, Newman says their results indicate that not everyone – including those in high-risk communities – would automatically accept an HIV vaccine in the event that one was developed.
The factors that most influenced participants' acceptance of the theoretical vaccines were efficacy (how effective a vaccine would be against HIV) followed by side effects and cost. The team also found that about 10 percent of at-risk adults might increase their sexual risk behaviours – such as not using condoms – if vaccinated against HIV.
"Merely having a vaccine available doesn't mean it gets to the people who need it – a fact that is evidenced by the issues we're seeing now around H1N1 vaccines," says Newman. "If we want HIV vaccines to be acceptable and accessible to people, we need to consider all of these factors before we have a safe and relatively effective vaccine on the market."
Education is key, says Newman. People need to trust that a vaccine is good and will be effective. They need to understand in lay terms how it works. They need to know what scientists mean when they talk about a vaccine's efficacy, and they need to know they shouldn't increase their risk behaviours simply because they're being vaccinated. Initial HIV vaccines may be only partially effective in preventing HIV infection; they may be a great addition to existing prevention methods, but not a replacement.
The research also indicates that governments should consider how to subsidize vaccines to make sure they are affordable to those who are least able to pay.
Newman says the study provides a template that should be replicated in the developing world, which carries 95 percent of the global HIV burden.
"In order to ensure future HIV vaccines are acceptable to those who need them, we must start acting now," says Newman. "Formative research that aims to anticipate and address consumer preferences and larger challenges in the introduction of new health and prevention technologies is a cost-effective means to promote success."
For more information on the study, appearing in the December edition of Health Services Research, please contact:
Peter A. Newman, lead author: email@example.com
April Kemick, media relations officer: 416-978-5949 or firstname.lastname@example.org
April Kemick | EurekAlert!
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy